May 7, 2024

Invitae Receives Court Approval for Sale to Labcorp

Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseases Key milestone reached in Invitae's Chapter 11 process BURLINGTON, N.C. and SAN FRANCISCO , May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive
Read more »
<span>Breathing new life into inhaled medicines</span>
May 6, 2024

Breathing new life into inhaled medicines

Taking an inhaled medication can be as easy as taking a breath. This simple and painless drug-delivery method has always been a preferred option for respiratory drugs. The inhaled medicine market is booming. There are more than 100 pharmaceutical compounds in development for the treatment of respiratory ailments, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). It is also quickly becoming the method of choice for a variety of more diverse and systemic therapies as an alternative to needle injections or other invasive applications, which are less desirable to patients—such as for Parkinson’s disease, seizures, diabetes and analgesics.
Read more »
<span>Navigating the genetic complexity of autism spectrum disorder (ASD) with insights from Labcorp's Reveal® SNP Microarray Pediatric Test</span>
May 3, 2024

Navigating the genetic complexity of autism spectrum disorder (ASD) with insights from Labcorp's Reveal® SNP Microarray Pediatric Test

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder typically characterized by deficits in social behaviors and communication skills emerging within the first three years of life. Given ASD’s spectrum nature and the absence of clear biomarkers or diagnostic measures, it’s important to understand ASD’s genetic origins.
Read more »